Literature DB >> 6780634

Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.

H Käyhty, V Karanko, H Peltola, S Sarna, P H Mäkelä.   

Abstract

The persistence of antibodies to the capsular polysaccharide of group A Neissera meningitidis was studied in 2,030 persons vaccinated at the age of 10 weeks to 19 years and followed for three years. Both the initial antibody response and the persistence of elevated serum titers of antibody were markedly age-dependent. In infants younger than 12 months, a statistically significant antibody response was obtained after a booster dose of vaccine and was maintained for one year. In infants aged 12-17 months, the response after booster vaccination was higher and was maintained for two years. Children older than 17 months did not receive a booster injection. The initial response in the age group 18-23 months was good, but the decline of antibody level was more rapid, so that an elevated antibody titer was not maintained for more than one year. With increasing age, the decrease of the vaccination-induced antibody levels was progressively slower throughout the age bracket studied.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6780634     DOI: 10.1093/infdis/142.6.861

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  COVID-19 and lessons learned from the pandemic wave of meningococcal meningitis (1985-1990).

Authors:  Mohammed Osman Swar
Journal:  Sudan J Paediatr       Date:  2020

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis.

Authors:  Merryn Voysey; Dominic F Kelly; Thomas R Fanshawe; Manish Sadarangani; Katherine L O'Brien; Rafael Perera; Andrew J Pollard
Journal:  JAMA Pediatr       Date:  2017-07-01       Impact factor: 16.193

4.  A thymus-independent (type 1) phosphorylcholine antigen isolated from Trichinella spiralis protects mice against pneumococcal infection.

Authors:  P L Lim; W F Choy
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

Review 5.  Vaccines for prevention of meningococcal disease.

Authors:  C E Frasch
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

6.  Comparison of radioimmunoassay and enzyme-linked immunosorbent assay in measurement of antibodies to Neisseria meningitidis group A capsular polysaccharide.

Authors:  E C Beuvery; M H Kayhty; A B Leussink; V Kanhai
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

7.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

Authors:  P K Holder; S E Maslanka; L B Pais; J Dykes; B D Plikaytis; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

Review 10.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.